GEP20156289B - New aminopyrazoloquinazolines - Google Patents
New aminopyrazoloquinazolinesInfo
- Publication number
- GEP20156289B GEP20156289B GEAP201113008A GEAP2011013008A GEP20156289B GE P20156289 B GEP20156289 B GE P20156289B GE AP201113008 A GEAP201113008 A GE AP201113008A GE AP2011013008 A GEAP2011013008 A GE AP2011013008A GE P20156289 B GEP20156289 B GE P20156289B
- Authority
- GE
- Georgia
- Prior art keywords
- aminopyrazoloquinazolines
- new
- basis
- formula
- pharmaceutical preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
- C07D493/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10170683 | 2010-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20156289B true GEP20156289B (en) | 2015-05-25 |
Family
ID=43037625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP201113008A GEP20156289B (en) | 2010-07-23 | 2011-07-22 | New aminopyrazoloquinazolines |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8735386B2 (enExample) |
| EP (1) | EP2595987B1 (enExample) |
| JP (1) | JP5991974B2 (enExample) |
| KR (1) | KR20130132394A (enExample) |
| CN (1) | CN103097388A (enExample) |
| AP (1) | AP2012006640A0 (enExample) |
| AR (1) | AR082850A1 (enExample) |
| AU (1) | AU2011281504A1 (enExample) |
| BR (1) | BR112013000107A2 (enExample) |
| CA (1) | CA2803467A1 (enExample) |
| CL (1) | CL2012003745A1 (enExample) |
| CO (1) | CO6670575A2 (enExample) |
| EA (1) | EA201201661A1 (enExample) |
| EC (1) | ECSP13012448A (enExample) |
| GE (1) | GEP20156289B (enExample) |
| MA (1) | MA34389B1 (enExample) |
| MX (1) | MX2013000821A (enExample) |
| PE (1) | PE20131143A1 (enExample) |
| PH (1) | PH12013500152A1 (enExample) |
| SG (1) | SG187548A1 (enExample) |
| TW (1) | TW201217380A (enExample) |
| UY (1) | UY33526A (enExample) |
| WO (1) | WO2012010704A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013110585A1 (en) | 2012-01-23 | 2013-08-01 | Boehringer Ingelheim International Gmbh | 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors |
| US9376437B2 (en) | 2013-03-13 | 2016-06-28 | Oncoceutics, Inc | 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, salts thereof and methods of using the same in combination therapy |
| ES2724331T3 (es) * | 2013-11-15 | 2019-09-10 | Oncoceutics Inc | 7-Bencil-4-(2-metilbencil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sales de la misma y procedimientos de uso |
| MD3805222T2 (ro) | 2015-01-30 | 2025-04-30 | Oncoceutics Inc | Derivați de 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-hexahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(1H)-ona, sărurile acestora și utilizarea acestora în terapie |
| WO2016180843A1 (en) * | 2015-05-13 | 2016-11-17 | Boehringer Ingelheim International Gmbh | New 5,8-dimethyl-9-phenyl-5,8-dihydro-6h-pyrazolo[3,4-h]quinazolin-2- yl)-(1 h-pyrazol-3-yl)-amines and derivatives as igf-1 r/ir inhibitors |
| CA3039012C (en) | 2016-11-11 | 2021-08-24 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof |
| JP6915907B2 (ja) * | 2017-05-26 | 2021-08-04 | 江▲蘇▼新元素医▲薬▼科技有限公司Ｊｉａｎｇｓｕ Ａｔｏｍ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | 尿酸排泄を促進するｕｒａｔ１阻害剤 |
| CN107383019B (zh) * | 2017-07-28 | 2019-10-15 | 江苏艾凡生物医药有限公司 | 吡唑并[4,3-h]喹唑啉类化合物及其用途 |
| CN111566101B (zh) * | 2018-04-24 | 2023-08-11 | 上海海雁医药科技有限公司 | Cdk4/6抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
| SG11202109443QA (en) | 2018-11-02 | 2021-09-29 | Fount Bio Inc | Crosslinked materials |
| WO2020160321A1 (en) * | 2019-01-30 | 2020-08-06 | Yale University | Compounds, compositions, and methods for treating fibrosis |
| US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
| TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
| MX2021010669A (es) * | 2019-03-07 | 2021-09-28 | BioNTech SE | Proceso para la preparacion de una imidazoquinolina sustituida. |
| WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
| BR112021020951A2 (pt) * | 2019-04-19 | 2021-12-14 | Fount Bio Inc | Dispensação e retenção de agentes ativos dentro da pele |
| US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| US11447494B2 (en) | 2019-05-01 | 2022-09-20 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
| CN116348458A (zh) | 2019-08-14 | 2023-06-27 | 因赛特公司 | 作为cdk2抑制剂的咪唑基嘧啶基胺化合物 |
| CN119930611A (zh) | 2019-10-11 | 2025-05-06 | 因赛特公司 | 作为cdk2抑制剂的双环胺 |
| JP2023529867A (ja) | 2020-06-05 | 2023-07-12 | キネート バイオファーマ インク． | 線維芽細胞増殖因子受容体キナーゼの阻害剤 |
| CN111960974A (zh) * | 2020-08-28 | 2020-11-20 | 山东潍坊润丰化工股份有限公司 | 一种烯草酮中间体的合成方法 |
| WO2022166725A1 (zh) * | 2021-02-08 | 2022-08-11 | 南京明德新药研发有限公司 | 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物 |
| US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
| US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0856001B1 (en) * | 1995-10-02 | 2002-08-28 | F. Hoffmann-La Roche Ag | Pyrimidine derivatives as 5ht2c receptor antagonists |
| EA010904B1 (ru) | 2003-05-22 | 2008-12-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ |
| CN1897950A (zh) * | 2003-10-14 | 2007-01-17 | 惠氏公司 | 稠合芳基和杂芳基衍生物及其使用方法 |
-
2011
- 2011-07-20 US US13/187,100 patent/US8735386B2/en active Active
- 2011-07-21 UY UY0001033526A patent/UY33526A/es not_active Application Discontinuation
- 2011-07-22 PE PE2013000125A patent/PE20131143A1/es not_active Application Discontinuation
- 2011-07-22 GE GEAP201113008A patent/GEP20156289B/en unknown
- 2011-07-22 CA CA2803467A patent/CA2803467A1/en not_active Abandoned
- 2011-07-22 PH PH1/2013/500152A patent/PH12013500152A1/en unknown
- 2011-07-22 AU AU2011281504A patent/AU2011281504A1/en not_active Abandoned
- 2011-07-22 AP AP2012006640A patent/AP2012006640A0/xx unknown
- 2011-07-22 AR ARP110102670A patent/AR082850A1/es unknown
- 2011-07-22 KR KR1020137003430A patent/KR20130132394A/ko not_active Withdrawn
- 2011-07-22 EA EA201201661A patent/EA201201661A1/ru unknown
- 2011-07-22 WO PCT/EP2011/062683 patent/WO2012010704A1/en not_active Ceased
- 2011-07-22 JP JP2013520164A patent/JP5991974B2/ja active Active
- 2011-07-22 MA MA35577A patent/MA34389B1/fr unknown
- 2011-07-22 EP EP11734158.6A patent/EP2595987B1/en active Active
- 2011-07-22 SG SG2013003645A patent/SG187548A1/en unknown
- 2011-07-22 MX MX2013000821A patent/MX2013000821A/es active IP Right Grant
- 2011-07-22 BR BR112013000107A patent/BR112013000107A2/pt not_active IP Right Cessation
- 2011-07-22 CN CN201180043930XA patent/CN103097388A/zh active Pending
- 2011-07-22 TW TW100126062A patent/TW201217380A/zh unknown
-
2012
- 2012-12-28 CL CL2012003745A patent/CL2012003745A1/es unknown
-
2013
- 2013-01-22 CO CO13011464A patent/CO6670575A2/es active IP Right Grant
- 2013-02-19 EC ECSP13012448 patent/ECSP13012448A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130132394A (ko) | 2013-12-04 |
| EA201201661A1 (ru) | 2013-07-30 |
| WO2012010704A1 (en) | 2012-01-26 |
| AP2012006640A0 (en) | 2012-12-31 |
| AU2011281504A1 (en) | 2013-01-10 |
| BR112013000107A2 (pt) | 2016-05-17 |
| CO6670575A2 (es) | 2013-05-15 |
| TW201217380A (en) | 2012-05-01 |
| EP2595987A1 (en) | 2013-05-29 |
| JP5991974B2 (ja) | 2016-09-14 |
| JP2013532652A (ja) | 2013-08-19 |
| MX2013000821A (es) | 2013-05-30 |
| CL2012003745A1 (es) | 2013-05-31 |
| PH12013500152A1 (en) | 2013-02-18 |
| UY33526A (es) | 2012-02-29 |
| AR082850A1 (es) | 2013-01-16 |
| EP2595987B1 (en) | 2018-04-18 |
| MA34389B1 (fr) | 2013-07-03 |
| CA2803467A1 (en) | 2012-01-26 |
| ECSP13012448A (es) | 2013-03-28 |
| US8735386B2 (en) | 2014-05-27 |
| SG187548A1 (en) | 2013-03-28 |
| CN103097388A (zh) | 2013-05-08 |
| US20120238542A1 (en) | 2012-09-20 |
| PE20131143A1 (es) | 2013-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20166484B (en) | Protein kinase inhibitors | |
| GEP201706703B (en) | Boronate ester compounds and pharmaceutical compositions thereof | |
| GEP201706624B (en) | Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment | |
| GEP201706725B (en) | Compounds and compositions as inhibitors of mek | |
| GEP20146125B (en) | Aminopyrimidines as syk inhibitors | |
| GEP20146134B (en) | Inhibitors of hepatitis c virus replication | |
| GEP20156370B (en) | Fluoro-pyridinone derivatives useful as antibacterial agents | |
| GEP20166443B (en) | Heterocyclic compound and use thereof | |
| GEP20146060B (en) | Pyridyl inhibitors of hedgehog signalling | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| GEP20156389B (en) | Oxazolidin-2-one compounds and their usage as pi3ks inhibitors | |
| GEP201606598B (en) | Heteroaromatic compounds as dopamine d1 ligands | |
| GEP20146102B (en) | Compounds and compositions as protein kinase inhibitors | |
| PH12012501631A1 (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd | |
| GEP201706691B (en) | Substituted phthalazin-1 (2h)-one derivatives as selecti- ve inhibitors of poly (adp-ribose) polymerase-1 | |
| GEP201606597B (en) | Bruton's tyrosine kinase inhibitors | |
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| ZA201902335B (en) | Pharmaceutical compounds | |
| PH12012501630A1 (en) | Pyrimidine derivatives and their use in the treatment of respiratory diseases such as copd | |
| EP4327886A3 (en) | Pyrimido- pyridazinone compounds and use thereof | |
| GEP20135927B (en) | 1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression | |
| UA107667C2 (uk) | Лікарські сполуки, що модулюють активність піруваткінази-м2, композиції на їх основі та застосування при лікуванні раку | |
| GEP201706621B (en) | Benzamides | |
| GEP20156346B (en) | Imidazole derivatives as pde10a enzyme inhibitors | |
| GEP20146099B (en) | Fused imidazole carboxamides as trpv3 modulators |